PEG minocycline-liposomes ameliorate CNS autoimmune disease

Medicine & Life Sciences

• Autoimmune Diseases of the Nervous System 94%
• Minocycline 77%
• Polyethylene Glycols 69%
• Central Nervous System Diseases 68%
• Liposomes 61%
• Matrix Metalloproteinase 9 33%
• Central Nervous System 15%
• Leukocytes 12%
• Multiple Sclerosis 9%
• Injections 5%
• Tetracycline 5%
• Animals 5%
• Intraperitoneal Injections 5%
• Therapeutics 5%
• Intravenous Injections 4%
• Biological Availability 4%
• Blood Cells 4%
• Spinal Cord 4%
• Cell Count 3%
• Kinetics 3%
• Animal Models 3%
• Drug Therapy 3%
• Brain 2%
• In Vitro Techniques 2%

Agriculture & Biology

• minocycline 91%
• autoimmune diseases 85%
• central nervous system 62%
• polyethylene glycol 60%
• gelatinase B 45%
• sclerosis 14%
• leukocytes 13%
• injection 7%
• mononuclear leukocytes 6%
• spinal cord 5%
• splenocytes 5%
• intraperitoneal injection 5%
• intravenous injection 5%
• tetracycline 5%
• drug therapy 5%
• bioavailability 4%
• animal models 4%
• animals 4%
• adverse effects 4%
• therapeutics 4%
• mouth 4%
• brain 3%
• kinetics 3%
• cells 1%

Chemical Compounds

• Minocycline 100%
• Poly(ethylene Glycol) 49%
• Intraperitoneal 11%
• Cord 10%
• Tetracycline 10%
• Bioavailability 8%
• Liposome 8%
• Amount 3%
• Time 3%